A Comparison of 2 Modes of Administration of Recombinant Interleukin-2: Continuous Intravenous Infusion Alone Versus Subcutaneous Administration plus Interferon Alpha in Patients with Advanced Renal Cell Carcinoma.-Reference-Cited by-同舟云学术

A Comparison of 2 Modes of Administration of Recombinant Interleukin-2: Continuous Intravenous Infusion Alone Versus Subcutaneous Administration plus Interferon Alpha in Patients with Advanced Renal Cell Carcinoma.

Published:1993-01 Issue:2 Volume:8 Page:123-136
ISSN:1062-8401
Container-title:Cancer Biotherapy
language:en
Short-container-title:Cancer Biotherapy

Author:

Palmer P.A.,Atzpodien J.,Philip T.,Negrier S.,Kirchner H.,Von der Maase H.,Geertsen P.,Evers P.,Loriaux E.,Oskam R.,Roest G.,Vinke J.,Franks C.R.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.1993.8.123

Reference5 articles.

1. Interleukin-2: Inception, Impact, and Implications

2. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

3. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of interleukin-2 in immunostimulation and immunosuppression;Journal of Experimental Medicine;2019-10-14

2. The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer;Cytokine: X;2019-03

3. Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion;Journal of Clinical Oncology;2011-02-01

4. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer;Cancer Immunology, Immunotherapy;2009-08-19

5. Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results;Renal Cell Carcinoma;2009